Please login to the form below

Not currently logged in
Email:
Password:

EU drops Boehringer Ingelheim patent probe

The EU has closed antitrust investigations regarding Boehringer Ingelheim's COPD drugs

The European Union has dropped an antitrust investigation into Boehringer Ingelheim's patents for chronic obstructive pulmonary disease (COPD) treatments.

The decision came as German firm Boehringer Ingelheim agreed to remove "blocking positions" that Spanish rival Almirall alleged prevented sales of its treatments for COPD.

In addition, the EU's antitrust agency said pharmaceutical companies struck only three “problematic” patent- settlement deals in 2010 that may be used to delay the sale of generic versions of medicines.

Joaquín Almunia, commission vice president in charge of competition policy, said: "I note with satisfaction that the number of patent settlements potentially problematic under EU antitrust law continues to decrease without calling into account companies' legitimate right to settle disputes amicably.

"The commission will remain vigilant that companies' behaviour respect antitrust law and do not delay entry of cheaper pharmaceuticals," he added.

7th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...

Infographics